Clever combo: multi-modality imaging developed by novel optics

Article

Funding novel optics and imaging software encourages the evolution of multi-modality imaging and provides more business opportunities.

Funding novel optics and imaging software encourages the evolution of multi-modality imaging and provides more business opportunities, according to the latest analysis from Frost and Sullivan.

The publication, "Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging (Technical Insights)", demonstrates that the development of novel optics, data acquisition methods and image processing software has significantly encouraged the evolution of optical imaging technologies.

Optical imaging, at both macroscopic and microscopic levels, are frequently used by clinicians to image tissues with enhanced contrast and resolution capabilities.

Prasanna Vadhana Kannan, Senior Research Analyst at Technical Insights, said, "Technology trends are moving from conventional confocal microscopy to optical coherence tomography (OCT), with the adoption of newer technologies such as adaptive optics and polarization imaging in ophthalmology. Several start-ups are developing innovative technologies, most of which are in the near completion and advanced phases of clinical approval in the optical imaging market."

Kannan continued, "OCT is truly an easy-to-use modality that provides digital cellular 2-D and 3-D imaging solutions for clinical and research pathology lab application needs on fixed or fresh tissue. Further refinement could result in achieving significantly higher resolution capabilities and better differentiation of cancerous lesions, embryology studies, and stem cells (involving therapeutics research)."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.